Cargando…

Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration

BACKGROUND: To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD). METHODS: A retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kähkönen, Mikael, Tuuminen, Raimo, Aaltonen, Vesa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399828/ https://www.ncbi.nlm.nih.gov/pubmed/34454473 http://dx.doi.org/10.1186/s12886-021-02076-1

Ejemplares similares

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale, Claudia, et al.
Publicado: (2018)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Relationship Between Prolonged Intraocular Inflammation and Macular Edema After Cataract Surgery
por: Aaronson, Alexander, et al.
Publicado: (2021)

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
por: Ferrone, Philip J, et al.
Publicado: (2014)

The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
por: Shin, Kyung-Hoon, et al.
Publicado: (2016)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine, Ilkka, et al.
Publicado: (2017)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Matsubara, Hisashi, et al.
Publicado: (2016)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study
por: Ogura, Yuichiro, et al.
Publicado: (2015)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Wang, Jia-Kang, et al.
Publicado: (2016)

Immediate effect of intravitreal injection of bevacizumab on intraocular pressure
por: Lemos-Reis, Ricardo, et al.
Publicado: (2014)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes
por: Karakurt, Yucel, et al.
Publicado: (2018)

Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results
por: Ugurtay, Ozgul, et al.
Publicado: (2021)

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
por: Gyenes, Andrea, et al.
Publicado: (2023)

Autophagy Genes for Wet Age-Related Macular Degeneration in a Finnish Case-Control Study
por: Paterno, Jussi J., et al.
Publicado: (2020)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation
por: Motarjemizadeh, Qader, et al.
Publicado: (2018)

Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes
por: Dingerkus, Vita Louisa Sophie, et al.
Publicado: (2022)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration
por: Ozawa, Yoko, et al.
Publicado: (2023)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
por: Stewart, Michael W
Publicado: (2012)

Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration
por: Reis, Gustavo MSM, et al.
Publicado: (2017)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2017)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
por: Urban, Beata, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_de0gabbf0knl5vjinpdnll4rsu